Log In
BCIQ
Print this Print this
 

Sicorten Plus

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionTopical cream formulation of halometasone and triclosan
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationDermatitis
Indication DetailsTreat corticosteroid-responsive dermatitis and eczema, including seborrheic dermatitis, localized neurodermatitis and nummular eczema
Regulatory Designation
PartnerLansen Pharmaceutical Holdings Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$9.5M

$8.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/07/2014

$9.5M

$8.0M

0

Get a free BioCentury trial today